Novel mutations introduced at the β-site of amyloid β protein precursor enhance the production of amyloid β peptide by BACE1 in vitro and in cells

Abnormal production and accumulation of amyloid-β peptide (Aβ) plays a major role in the pathogenesis of Alzheimer’s disease (AD). β-secretase (BACE1) is responsible for the cleavage at the β-site in amyloid β protein precursor (AβPP/APP) to generate the N-terminus of Aβ. Here we report the stepwise identification and characterization of a novel APP-β-site mutant, “NFEV” (APP NFEV) in vitro and in cells. In vitro, the APP NFEV exhibits 100-fold enhanced cleavage rate relative to the “wild-type” substrate (APPwt) and 10-fold increase relative to the Swedish-type mutation variant (APPsw). In cells, it was preferably cleaved among 24 APP β-site mutations tested. More importantly, the APP NFEV mutant failed to generate any detectable Aβ peptides in BACE1-KO mouse fibroblast cells. The production of Aβ peptides was restored by co-transfecting human BACE1, demonstrating that BACE1 is the only enzyme responsible for the processing of APP NFEV in these cells. Analysis of APP NFEV cleavage products secreted in the media revealed that in cells BACE1 cleaves APP NFEV at the position between NF and EV, identical to that observed in vitro. A BACE inhibitor blocked the processing of the APP NFEV β-site in vitro and in cells. Our data indicates that the “NFEV” mutant is not only an enhanced substrate for BACE1 in vitro, but also a specific substrate for BACE1 in cells.